Literature DB >> 9354669

Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease.

V Hurez1, M D Kazatchkine, T Vassilev, S Ramanathan, A Pashov, B Basuyaux, Y de Kozak, B Bellon, S V Kaveri.   

Abstract

Normal human serum contains IgM antibodies that regulate the natural autoantibody activity of IgG in autologous serum. In the present study, we show that pooled normal human IgM (IVIgM) purified from plasma of more than 2,500 healthy donors and processed in a similar fashion to that of therapeutic preparations of pooled normal human IgG (IVIg) suppresses activity of IgG autoantibodies purified from the serum of patients with autoimmune diseases in vitro. The inhibitory effect of IVIgM was greater or equivalent to that of IVIg on a molar basis. We show that IVIgM contains anti-idiotypic antibodies directed against idiotypic determinants of autoantibodies, in particular by showing that Sepharose-bound IVIgM selectively retained F(ab')2 fragments of IgG autoantibodies. The infusion of (Lewis x Brown-Norway) F1 rats with IVIgM protected the animals against experimental autoimmune uveitis induced by immunization with the soluble retinal S antigen, as evidenced by clinical scoring and histopathological analysis. The present findings provide a rationale for considering pooled IgM for immunomodulation of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354669

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

Review 2.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Intravenous immunoglobulins. Current understanding and future directions.

Authors:  S Jolles; S V Kaveri; J Orange
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

6.  Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

Authors:  A E Warrington; K Asakura; A J Bieber; B Ciric; V Van Keulen; S V Kaveri; R A Kyle; L R Pease; M Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 7.  Is There a Role for Natural Antibodies in Rejection Following Transplantation?

Authors:  Emmanuel Zorn; Sarah B See
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin).

Authors:  D Nachbaur; M Herold; A Gächter; D Niederwieser
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

Review 10.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.